Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis.

Related Articles

Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis.

Curr Top Med Chem. 2016 Apr 13;

Authors: Grewal AS, Pandita D, Bhardwaj S, Lather V

Abstract
Human African trypanosomiasis (HAT, better called as sleeping sickness), caused by two morphologically identicalprotozoan parasite Trypanosoma bruceiis transmitted by the bite of tsetse fliesof Glossinagenus, mainly in the rural areas of the sub-Saharan Africa.HAT is one of the neglected tropical diseases and is characterized by sleep disturbance as the main symptom, hence is called as sleeping sickness. As it is epidemic in the poorest population of Africa, there is limited availability of safe and cost-effective tools for controlling the disease. Trypanosoma bruceigambiensecauses sleeping sickness in Western and Central Africa,whereasTrypanosoma bruceirhodesienseis the reason for prevalence of sleeping sickness in Eastern and Southern Africa. For the treatment of sleeping sickness, only five drugs have been approved suramin, pentamidine, melarsoprol, eflornithine and nifurtimox. Various small molecules of diverse chemical nature have been synthesizedfortargeting HAT and many of them are in the clinical trialsincluding fexinidazole (phase I completed) and SCYX-7158 (advanced in phase I). The present work has been planned to reviewvarious types of small molecules developed in the last 10 years having potent antitrypanosoma activity likely to be beneficial in sleeping sickness along withdifferent natural anti-HAT agents.

PMID: 27072715 [PubMed - as supplied by publisher]

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1p0lDR9
via IFTTT